Oligometastatic Prostate Cancer Treatment Outcomes in Chinese Multicenter Study

A multicenter retrospective study of 160 oligometastatic prostate cancer patients from five Chinese medical centers between May 2010 and May 2023. It compares perioperative and oncological outcomes for patients receiving neoadjuvant hormonal therapy plus robot-assisted radical prostatectomy versus standard therapy alone, with a median postoperative follow-up of 52 months.

Use Cases

• Compare operative time and blood loss between NHT and standard therapy groups to evaluate surgical efficiency.
• Analyze positive surgical margin rate and pathological T-stage downstaging to assess treatment impact on pathology.
• Model biochemical progression-free survival (bPFS) and radiological progression-free survival (rPFS) using subgroup variables like biopsy Gleason score ≥8.
• Evaluate the incidence of ADT-related adverse events and subsequent treatment rates between the two patient cohorts.

Strengths

• Contains data from 160 patients across five medical centers.
• Provides a median postoperative follow-up period of 52 months.
• Compares two distinct treatment groups with 80 patients each.

Limitations

• Small sample size of 160 patients limits statistical power for some subgroup analyses.
• Retrospective study design introduces potential for selection bias and confounding.
• Data is contained in a DOCX file, requiring extraction for computational analysis.

Provenance

Source

figshare, authored by Yujie Dong.

Collection Method

Multicenter retrospective study.

Time Range

May 2010 to May 2023.

Freshness

null

Geography

Five medical centers in China.